Parinda Parikh
Child & Adolescent Psychiatry · White Plains, NYNPI 1851353213
Payments from drug & device makers
Across 1,430 payments — averaging $129.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$45K
- AbbVie$44K
- Otsuka America Pharmaceutical, Inc.$42K
- Teva Pharmaceuticals USA, Inc.$28K
- Alkermes, Inc.$10K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- plus $12K from 28 others
What the payments were for
- Consulting fees$4,1202%
- Speaking & faculty fees$139,27175%
- Travel & lodging$15,0708%
- Food & beverage$25,90314%
- Education$3740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$184,738 in reported general payments places this provider in the 95th percentile of 317 child & adolescent psychiatry providers in New York.
See all child & adolescent psychiatry providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 38 | $107,813 |
| LybalviOlanzapine/Samidorphan Malate | 39 | $57,633 |
| Invega SustennaPaliperidone Palmitate | 21 | $44,344 |
| VraylarCariprazine Hcl | 23 | $37,826 |
| AuvelityDextromethorphan Hbr/Bupropion | 30 | $35,700 |
| RexultiBrexpiprazole | 21 | $29,225 |
| TrintellixVortioxetine Hydrobromide | 39 | $23,238 |
| ZoloftSertraline Hcl | 14 | $6,771 |
| Jornay PmMethylphenidate Hcl | 15 | $6,176 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $5,236 |
| Divalproex Sodium ErDivalproex Sodium | 44 | $1,682 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 17 | $1,544 |
| Clozapine | 56 | $1,403 |
| Divalproex Sodium | 24 | $1,318 |
| Sertraline Hcl | 42 | $1,020 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada, Lybalvi | $10,221 | $165,44677 claims |
| Johnson & JohnsonInvega Sustenna | $631 | $44,34421 claims |
| AbbVieVraylar | $43,805 | $37,82623 claims |
| Axsome Therapeutics, Inc.Auvelity | $510 | $35,70030 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $42,293 | $29,22521 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $543 | $28,47450 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $759 | $6,17615 claims |
| Almatica Pharma LLCSertraline Hcl | $381 | $1,02042 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 317 child & adolescent psychiatry providers in New York.
Other child & adolescent psychiatry in White Plains
- Jonathan WachtelWhite Plains$7K
- Sunil SaxenaWhite Plains$6K
- Alexander KolevzonNew York$490K
- Jeffrey NewcornNew York$465K
- Matthew LorberNew York$398K
- Mitchell CabisudoNew Windsor$346K
- Aleksandra DjukicBronx$332K
- Jeremy Veenstra-VanderweeleNew York$224K
- John MarinoCanandaigua$70K
- Beth SmithBuffalo$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.